SecBot SecBot

VERA

Vera Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001831828 Biotech & Drug Discovery
$28.10 −0.94 (−3.24%)
Nov 13 4:00 PM ET · prev $29.04
Market cap
$2.1B
Mid cap
Consensus
Buy
85% Buy or better · 20 analysts
Median target
$75.00
+167% · range $29.00–100.00
1 year
−4.6%
from $29.46 · Nov 17
30 days
−2.8%
from $28.92
52-week range
$26.74–55.67
−50% from high · low Oct 14
Avg volume 20D
1.54M
shares / day
Short interest
12.14M
≈16.8% of shares · −10.6%
Days to cover
8.5
at average volume
Insider net
−$7.1M
0 buyers · 7 sellers · since Feb 4
New fund stakes
0
Q3 2026 13F · 1 exit
Filing reports
23
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 4 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $7.1M.

  • InstitutionsBULLISH

    Q3 2026: 31 added (0 new), 13 trimmed or exited.

  • AnalystsBULLISH

    17 of 20 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.536 → −$1.408 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −10.6% to 12.14M shares. 8.5 days to cover, ≈16.8% of shares.

  • TrendRANGE

    10% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
DEUTSCHE BANK AG\ADD2,131,876$68.8M
Pictet Asset Management Holding SAADD1,839,245$59.4M
Qube Research & Technologies LtdTRIM792,368$25.6M
MORGAN STANLEYNEAR_EXIT687,353$22.2M
UBS Group AGDOUBLED523,130$16.9M
VOYA INVESTMENT MANAGEMENT LLCTRIM419,805$13.6M
Jump Financial, LLCADD235,854$7.6M
Nuveen, LLCTRIM204,461$6.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 85% rate it Buy or better
Strong Buy7Buy10Hold3Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +167%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Wedbush
MAINTAIN
MAINTAINNeutral
Nov 6, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 12, 2026Leerink Partners
INITIATE
INITIATEMarket Perform
Sep 8, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 17, 2026Wedbush
REITERATE
REITERATENeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$7.1M
sold · 7 insiders
DateInsiderTypeValue
Sep 15, 2026
Fordyce Marshall
PRESIDENT AND CEO
Sep 15, 2026
EXERCISE$53.6K
Sep 15, 2026
Fordyce Marshall
PRESIDENT AND CEO
Sep 15, 2026
SELL$684.5K
Sep 11, 2026
Young Joseph R
SVP, FINANCE, CHIEF ACCT OFFCR
Sep 11, 2026
EXERCISE$19.7K
Sep 2, 2026
Fordyce Marshall
PRESIDENT AND CEO
Sep 2, 2026
SELL$649.6K
Sep 2, 2026
Fordyce Marshall
PRESIDENT AND CEO
Sep 2, 2026
EXERCISE$53.6K
Aug 3, 2026
Boman Nancy Lee
Chief Regulatory Officer
Aug 3, 2026
AWARD44,987 sh
Aug 3, 2026
Boman Nancy Lee
Chief Regulatory Officer
Aug 3, 2026
AWARD63,011 sh
Jul 7, 2026
Fordyce Marshall
PRESIDENT AND CEO
Jul 7, 2026
SELL$95.9K

Earnings setup

Estimates
−$1.41
EPS estimate, this quarter
+8%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.41-$2.16–-$1.11+8.6%$22.0M
Next Q🔒 Fresh data, subscribers only
Current FY-$5.95-$6.61–-$5.65+4.8%$31.2M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
12,141,556
shares short
-10.6%
vs prior settlement
8.5
days to cover
≈16.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 6, 2026 Other
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 22, 2026 Press
Vera Therapeutics announced positive final efficacy results from the ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in…
Impact 8/10
Sep 30, 2026 Inst.
DEUTSCHE BANK AG\ · ADD
2,131,876 shares ($68.8M)
Sep 30, 2026 Inst.
Pictet Asset Management Holding · ADD
1,839,245 shares ($59.4M)
Sep 15, 2026 Insider
Fordyce Marshall acquired via exercise 18,500 shares
PRESIDENT AND CEO @ $2.90 ($53.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

23 filings · 2 press releases · 6 bullish · 7 bearish · 2 mixed · 8 neutral
All VERA filing & press-release reports (25)